[ad_1]
Following the approval of the Pfizer / BioNTech vaccine last year at the end of December, the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), approved the Oxford University / AstraZeneca vaccine for use in the UK. Health Secretary Matt Hancock described vaccine approval as a ‘massive step forward’ for the UK’s fight against coronavirus, and said vaccines were the ‘way out of the pandemic “.
In clinical trials, the Oxford / AstraZeneca vaccine has shown a strong immune response in adults of all ages.
The Oxford / AstraZeneca vaccine has a good safety record and has shown 70.4% efficacy in testing.
The vaccine was developed by scientists at AstraZeneca and the University of Oxford, and the UK was the first in the world to sign an agreement for the vaccine.
Approval of the Oxford vaccine was important to the UK vaccine deployment effort, as the UK government ordered 100 million doses of the Oxford / AstraZeneca vaccine – enough to vaccinate 50 million people with two doses.
READ MORE: Symptoms of a new strain of coronavirus: the sign on your back and chest
Specialized sites in Wales and Germany then divide the vaccine into vials ready for distribution.
When the Oxford / AstraZeneca vaccine was approved by the UK regulator last year, the government noted its investment in a £ 100million vaccine factory.
The government said: “The UK government has invested £ 100million to fund a cutting edge manufacturing innovation center in Braintree, Essex, in conjunction with the Cell and Gene Therapy Catapult, to speed up mass production of a Covid-19 vaccine in the UK.
“Due to its opening in December 2021, the Center will have the capacity to produce millions of doses of vaccine each month, ensuring that the UK has the capabilities to manufacture both vaccines and advanced medicines, including for emerging diseases, in the future.
[ad_2]
Source link